Siltuximab

(Sylvant)

Siltuximab

Drug updated on 11/13/2023

Dosage FormInjection (intravenous: 100 mg, 400 mg)
Drug ClassInterleukin-6 (IL-6) antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Product Monograph / Prescribing Information

Document TitleYearSource
Sylvant (siltuximab) Prescribing Information.2019EUSA Pharma (UK) Ltd., Breakspear Park, Hertfordshire

Systematic Reviews / Meta-Analyses